In one-year update, Alzheon goes big talk, but shows off little clinical data
As Biogen pulls its global Aduhelm applications left and right, Alzheon — another smaller Massachusetts-based biotech — claims (again) it has “industry-leading” data on its Alzheimer’s drug. In a field littered with drug failures, any clinical benefit would be a major breakthrough. But on that front, Alzheon came up empty-handed.
In a one-year update on its Phase II trial, Alzheon said that in 75 patients who took its oral drug ALZ-801 twice a day, it observed a 41% reduction from baseline in levels of phosphorylated tau, or p-tau, a brain protein which builds up in Alzheimer’s disease. Alzheon also said that its drug reduced the ratio of p-tau and a component of amyloid plaques, Aβ42, by 37%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
